Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Rai Staging System for Chronic Lymphocytic Leukemia (CLL)

    Stages chronic lymphocytic leukemia, similar to Binet Staging System.
    Favorite

    INSTRUCTIONS

    Use in patients with lymphocytosis (absolute lymphocytes ≥15,000/mm3 in blood and ≥40% lymphocytes in marrow). Lymph nodes, spleen, and liver are considered enlarged if palpable on exam.

    When to Use

    Do you use the Rai Staging System for CLL and want to contribute your expertise? Join our contributor team!

    No
    Yes
    No
    Yes
    No
    Yes
    No
    Yes
    No
    Yes

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights

    Advice

    Do you use the Rai Staging System for CLL and want to contribute your expertise? Join our contributor team!

    Formula

    Selection of the appropriate features (lymphocytosis must be present for all):

    Lymph nodes, spleen, liver

    Hemoglobin

    Platelet count

    Rai Stage

    No enlargement

    Near normal

    Near normal

    0

    Enlarged lymph nodes; no spleen or liver enlargement

    Near normal

    Near normal

    I

    Enlarged spleen; lymph nodes and liver may or may not be enlarged

    Near normal

    Near normal

    II

    May or may not be enlarged

    Low

    Near normal

    III

    Enlarged lymph nodes, spleen, or liver

    Low or near normal

    Low

    IV

    From American Cancer Society 2018.

    Low hemoglobin: ≤11 g/dL; low platelets: ≤100,000/mm³.

     

    Facts & Figures

    Interpretation:

    Rai Stage

    Risk group

    Overall survival

    0

    Low

    >10 years

    I/II

    Intermediate

    7 years

    III/IV

    High

    <4 years

    From Nabhan 2014.

    Dr. Kanti R. Rai

    About the Creator

    Kanti R. Rai, MD, is a principal investigator and professor at The Feinstein Institute for Medical Research in Manhasset, New York. He is also chief of the Chronic Lymphocytic Leukemia Research and Treatment Program at the North Shore-LIJ Cancer Institute. His primary research is focused on clinical leukemia and molecular therapy.

    To view Dr. Kanti R. Rai's publications, visit PubMed

    About the Creator
    Dr. Kanti R. Rai